Showing 2881-2890 of 5685 results for "".
- Hoya Surgical Optics to Acquire Ophthalmic Medical Device Companies Mid Labs, Fritz Ruckhttps://modernod.com/news/hoya-surgical-optics-to-acquire-ophthalmic-medical-device-companies-mid-labs-fritz-ruck/2479775/Hoya Surgical Optics announced that it has entered into a definitive agreement to acquire two medical device companies: US-based Mid Labs and Germany-based Fritz Ruck. Mid Labs is a California-based company focused on the research, innovation, development, engineering, and manufacturin
- Altris.AI Partners With Huvitz for Development of AI-Based Retinal Detectionhttps://modernod.com/news/altris-ai-the-new-era-of-retinal-diagnosis-is-coming/2479785/Artificial intelligence company Altris.Al announced it has signed an agreement with South Korean ophthalmic and optical medical equipment manufacturer Huvitz Co. aimed at the development of customized deep learning solutions for retinal diseases detection. Terms of the deal were not disclo
- Novaliq Raises New Capital to Accelerate the Commercialization of its Lead Products for Dry Eye Diseasehttps://modernod.com/news/novaliq-raises-new-capital-to-accelerate-the-commercialization-of-its-lead-products-for-dry-eye-disease/2479793/Novaliq announced it has raised $53 million to further support its late-stage products and earlier pipeline programs. Since inception, Novaliq has raised $115 million. The new investment is done by its lead investor dievini Hopp BioTech Holding, an active investor in Life and Health Scienc
- Department of Defense Grant for Clinical Trial of Stem Cell Therapy for Eye Injurieshttps://modernod.com/news/department-of-defense-grant-for-clinical-trial-of-stem-cell-therapy-for-eye-injuries/2479809/Researchers at the University of Illinois at Chicago have received a 4-year, $5.25 million grant from the U.S. Department of Defense to lead a multisite clinical trial to test the efficacy of a stem cell-based treatment for eye injuries. The treatment uses mesenchymal stem cells—cells that
- In-Clinic Hurdles for AI-Based Diabetic Retinopathy Detectionhttps://modernod.com/news/in-clinic-hurdles-for-ai-based-diabetic-retinopathy-detection/2479810/Researchers found mixed results when they tested an artificial intelligence (AI)‒based system for detecting diabetic retinopathy (DR) in a real-world primary care setting in Midland, Australia, according to a Medscape report. In th
- New Display Design Could Make Lightweight, Compact Smart Glasses a Realityhttps://modernod.com/news/new-display-design-could-make-lightweight-compact-smart-glasses-a-reality/2479811/Researchers have developed a fundamentally new approach to a see-through display for augmented reality, or smart glasses. By projecting images from the glass directly onto the eye, the new design could one day make it possible for a user to see information such as directions or restaurant ratings
- AAO: New Study Confirms Mediterranean Diet Prevents AMD Developmenthttps://modernod.com/news/aao-new-study-confirms-mediterranean-diet-prevents-a-leading-cause-of-blindness/2479827/Evidence is mounting that a poor diet plays an important role in the development of age-related macular degeneration (AMD). A large
- NovaBay Pharmaceuticals Names Jack McGovern Interim CEOhttps://modernod.com/news/novabay-pharmaceuticals-names-jack-mcgovern-interim-ceo/2479833/NovaBay Pharmaceuticals announced that Jack McGovern has been named interim Chief Executive Officer, expanding his responsibilities as Chief Financial Officer to include overseeing daily operations. Mark M. Sieczkarek, the company’s previous CEO, remains NovaBay’s Chairman and will focus on strat
- First FDA-Approved Iris Prosthesis Now Available in the United Stateshttps://modernod.com/news/veo-ophthalmics-launches-customflex-artificialiris-in-the-united-states/2479835/VEO Ophthalmics announced the launch of the ‘Customflex ArtificialIris,’ the first iris prosthesis available in the United States. The surgically implanted device received FDA approval on May 30, 2018 for use in children and adults for the treatment of iris defects resulting from cong
- PeptiDream Announces Drug Discovery and Development Agreement with Santen Pharmaceuticalhttps://modernod.com/news/peptidream-announces-drug-discovery-and-development-agreement-with-santen-pharmaceutical/2479839/PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company, announced that it has entered into a broad-based multi-target discovery and development agreement with Osaka-based Santen Pharmaceuticals. Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform